It has been widely demonstrated that patients starting treatment with immunomodulatory drugs may experience a change on plasma cells phenotype, and the use of drugs such as Daratumumab, that could mask the CD38 overexpressed molecule, can make even more difficult MM clones recognition (66). This evidence concerns the gene CD38 and Miyoshi myopathy.